Literature DB >> 23701657

Hydroxamate, a key pharmacophore exhibiting a wide range of biological activities.

Samuel Bertrand1, Jean-Jacques Hélesbeux, Gérald Larcher, Olivier Duval.   

Abstract

Naturally occurring hydroxamic acid derivatives are biosynthesized by microorganisms (siderophores) and plants (benzoxazinoids). Recent developments in drug discovery have highlighted the numerous biological and pharmacological properties that the hydroxamic acid function may possess, leading to therapeutic applications. These properties may be explained by its ability to chelate metals via the presence of two oxygen atoms. Their pharmacological activities can be divided into three groups. The first concerns the ability of these hydroxamic acid derivatives to scavenge metals (particularly iron), which leads to antioxidant, antimicrobial and metal detoxification activities. The latter is largely used to treat iron overload in patients. The second group of activities is related to their ability to inhibit metallo-enzymes, which gives them a wide range of pharmacological effects: antimicrobial, anti-inflammatory and antitumor. The third group is linked to the capacity of these compounds to generate nitric oxide, which confers hypotensive activity. However, hydroxamates exhibit relatively low stability in vivo, which can be overcome by the synthesis of appropriately designed analogs. For this purpose, many different strategies have been proposed. In this review, we compare and discuss the various synthetic pathways used to obtain the most complex of them, the N-substituted hydroxamic acids. We conclude that among numerous protocols reported so far, the direct N-substitution of hydroxamic acids, the acylation of the appropriate N-O derivative and the direct oxidation of the corresponding amide allow for the synthesis of a wide range of new biologically active compounds.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23701657     DOI: 10.2174/13895575113139990007

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  14 in total

1.  Desferrioxamine biosynthesis: diverse hydroxamate assembly by substrate-tolerant acyl transferase DesC.

Authors:  Jade L Ronan; Nadia Kadi; Stephen A McMahon; James H Naismith; Lona M Alkhalaf; Gregory L Challis
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

2.  WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-inflammatory properties via MKP-1 in LPS-stimulated RAW264.7 macrophages.

Authors:  Wei-Chuan Chen; Chia-Sheng Yen; Wei-Jan Huang; Ya-Fen Hsu; George Ou; Ming-Jen Hsu
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  WMJ-8-B, a novel hydroxamate derivative, induces MDA-MB-231 breast cancer cell death via the SHP-1-STAT3-survivin cascade.

Authors:  Yu-Fan Chuang; Shiu-Wen Huang; Ya-Fen Hsu; Meng-Chieh Yu; George Ou; Wei-Jan Huang; Ming-Jen Hsu
Journal:  Br J Pharmacol       Date:  2017-08-01       Impact factor: 8.739

4.  Development of effective biotransformation process for benzohydroxamic acid production using Bacillus smithii IIIMB2907.

Authors:  Hitesh Sharma; Rahul Vikram Singh; Ananta Ganjoo; Amit Kumar; Ravail Singh; Vikash Babu
Journal:  3 Biotech       Date:  2022-01-15       Impact factor: 2.406

5.  Gatorbulin-1, a distinct cyclodepsipeptide chemotype, targets a seventh tubulin pharmacological site.

Authors:  Susan Matthew; Qi-Yin Chen; Ranjala Ratnayake; Charles S Fermaintt; Daniel Lucena-Agell; Francesca Bonato; Andrea E Prota; Seok Ting Lim; Xiaomeng Wang; J Fernando Díaz; April L Risinger; Valerie J Paul; Maria Ángela Oliva; Hendrik Luesch
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

6.  WMJ-S-001, a novel aliphatic hydroxamate derivative, exhibits anti-angiogenic activities via Src-homology-2-domain-containing protein tyrosine phosphatase 1.

Authors:  Yi-Fang Chang; Ya-Fen Hsu; Pei-Ting Chiu; Wei-Jan Huang; Shiu-Wen Huang; George Ou; Joen-Rong Sheu; Ming-Jen Hsu
Journal:  Oncotarget       Date:  2015-01-01

7.  The effects of a novel aliphatic-chain hydroxamate derivative WMJ-S-001 in HCT116 colorectal cancer cell death.

Authors:  Yu-Han Huang; Shiu-Wen Huang; Ya-Fen Hsu; George Ou; Wei-Jan Huang; Ming-Jen Hsu
Journal:  Sci Rep       Date:  2015-10-29       Impact factor: 4.379

8.  Synthesis of Pyrrolo[1,2-a]pyrimidine Enantiomers via Domino Ring-Closure followed by Retro Diels-Alder Protocol.

Authors:  Beáta Fekete; Márta Palkó; Matti Haukka; Ferenc Fülöp
Journal:  Molecules       Date:  2017-04-13       Impact factor: 4.411

9.  A Novel Hydroxamate-Based Compound WMJ-J-09 Causes Head and Neck Squamous Cell Carcinoma Cell Death via LKB1-AMPK-p38MAPK-p63-Survivin Cascade.

Authors:  Chia-Sheng Yen; Cheuk-Sing Choy; Wei-Jan Huang; Shiu-Wen Huang; Pin-Ye Lai; Meng-Chieh Yu; Ching Shiue; Ya-Fen Hsu; Ming-Jen Hsu
Journal:  Front Pharmacol       Date:  2018-03-01       Impact factor: 5.810

10.  Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule.

Authors:  Issan Zhang; Maja Beus; Ursula Stochaj; Phuong Uyen Le; Branka Zorc; Zrinka Rajić; Kevin Petrecca; Dusica Maysinger
Journal:  Cell Death Discov       Date:  2018-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.